Publication of new white paper
06/09/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220906:nRSF3533Ya&default-theme=true
RNS Number : 3533Y Cellular Goods PLC 06 September 2022
Press release
6(th) September 2022
Cellular Goods PLC
('Cellular Goods' or 'the Company')
Publication of white paper exploring the top-five benefits of cannabinoids for
skincare applications
Cellular Goods (LSE: CBX), a UK-based wellness company providing premium
consumer products formulated with lab-produced cannabinoids, today announces
the publication of a new white paper, 'The 5 A's of Cannabinoid Skincare',
which explores the benefits cannabinoids, namely cannabidiol (CBD) and
cannabigerol (CBG), can have for the skin as powerhouse ingredients that
provide a multitude of benefits for skincare applications.
Cellular Goods refers to these benefits as the '5 A's of Cannabinoid Skincare'
owing to cannabinoids' strong ageing prevention, anti-inflammatory,
antioxidant, anti-bacterial, and anti-melanogenesis properties.
A growing body of robust scientific evidence is revealing that CBD and, in
particular CBG, are potent actives that can prevent the skin ageing effects of
UV radiation; inhibit the irritating effects of inflammation that accelerate
ageing in a process coined as "inflammaging"; protect skin from the damaging
effects of cellular oxidation and Reactive Oxygen Species (ROS); stop the
growth of blemish-causing bacteria; and through anti-melanogenesis brighten
skin and promote even skin tone.
It is these benefits that form the basis from which CBG and CBD can keep skin
healthy, smooth, firm and radiant. To date Vitamin C, retinoids, and
exfoliating acids are the active ingredients that have dominated the market as
ingredients addressing skin ageing, blemishes, and skin tone related concerns,
while they have proven to be effective, they are also known to cause skin
irritation and sensitivity. These traditional skincare ingredients fall short
of cannabinoids which provide a wider range of skincare benefits without the
risk of irritation.
In 'The 5 A's of Cannabinoid Skincare' white paper, the multifaceted benefits
of cannabinoids, are summarised with the intent of providing consumers and
formulators alike with an appreciation for the spectrum of advantages that CBG
and CBD can confer to skincare applications without being limited by their
irritation potential and risk of photosensitivity.
Ageing Prevention
In addition to having a higher tolerability allowing for more frequent use
than the existing catalogue of anti-ageing ingredients such as Vitamin C,
retinoids and exfoliating acids, cannabinoids present a proactive solution to
skin ageing thanks to their protective properties meaning they can complement
the use of other ingredients. Cellular Goods successfully confirmed these
benefits in an in-vivo study involving the Company's Rejuvenating Face Serum,
where 166 female participants reported that their skin was visibly
rejuvenated, appeared healthier, more radiant, and smoother after four weeks
of use. These result attest to the ageing prevention benefits of CBG and help
form the basis of the new Rejuvenating Range from Cellular Goods which
contains a proprietary blend of CBG and CBD.
Anti-Inflammatory
Findings from recent studies reveal CBG and CBD have a significant capacity to
prevent inflammation caused by common stimuli, including UV radiation and
bacterial pathogens, in a manner that is more effective than Vitamin C,
currently the most widely used active. For instance, Willow Biosciences,
Cellular Goods' supply partner, reported that pre-treatment of human dermal
fibroblasts with CBG or CBD was more effective than Vitamin C for preventing
inflammation caused by UVA radiation.
Antioxidant
Emerging research has demonstrated that cannabinoids such as CBG and, to a
lesser extent CBD, are equally if not more effective than Vitamin C at
protecting skin from the ageing effects of ROS activity and UV exposure. A
recent study published by Willow Biosciences found that CBG and, to a lesser
extent CBD, had markedly higher antioxidant capacities than Vitamin C, and
were consequentially more effective at preventing the formation of ROS (a key
driver of ageing) within human dermal fibroblasts.
Anti-Bacterial
CBG and CBD's potent anti-bacterial properties enable them to combat blemishes
without irritating skin through two distinct pathways, inhibiting the
inflammation caused by the pathogen Cutibacterium acnes (C. acnes) and also by
inhibiting this pathogen's growth, with CBG being more effective than CBD in
both instances. The overgrowth of C. acnes is one of the key mechanisms that
consistently contribute to the formation of blemishes. C. acnes' overgrowth
contributes to acne vulgaris, a dermatological condition affecting 9% of the
global population. While over-the-counter (OTC) treatment options targeting
specific factors of acne vulgaris' pathogenesis have emerged leveraging
retinoids and including active ingredients such as benzoyl peroxide, salicylic
acid, sulphur and tea tree oil the use of these actives is usually limited by
their irritation potential.
Anti-Melanogenesis
Excessive production of melanin in the skin can lead to hyperpigmentation, a
term used to describe uneven darker patches of skin that can be caused by
everything from acne scars to sun damage. This common condition has fuelled
the growth of a $6 billion skincare and treatment market. Through proprietary
research, Cellular Goods discovered that CBG is particularly effective for
enhancing the anti-melanogenesis outcomes of select skin brightening actives.
Additionally, cannabinoids benefit from enhanced effectiveness meaning that a
lower concentration is sufficient for achieving a specific level of efficacy
without the irritation risks of higher-strength formulas. Cellular Goods filed
a patent based on these results and is incorporating these insights into
ongoing product development.
The white paper is available to view at this link:
https://cellular-goods.com/learn/articles/science/white-paper-the-five-a-of-cannabinoid-skincare
(https://cellular-goods.com/learn/articles/science/white-paper-the-five-a-of-cannabinoid-skincare)
.
Anna Chokina, Chief Executive of Cellular Goods, said: "The benefits of
cannabinoids for maintaining healthy skin are both far-reaching and undeniable
and the release of today's white paper shows Cellular's commitment to
delivering science-backed cannabinoid-powered products that can support
healthier, youthful skin and elevate any robust skincare routine.
"The total addressable market for skincare products designed to support
age-prevention and tackle blemishes and hyperpigmentation is substantial and
Cellular Goods is proud to provide consumers with rejuvenating products that
can address this array of skincare concerns."
Alexia Blake, Head of Product Development and Product Research at Cellular
Goods, said: "Many conventional active ingredients prevalent in the market
across anti-aging, anti-blemish, antioxidant and hyperpigmentation products
have unpleasant side-effects that prevent frequent use. The body of research
explored in this white paper provides compelling evidence of the benefits of
CBG and CBD as safe, effective and well tolerated ingredients that present the
skincare solutions of the future.
"Emerging research into cannabinoids is continuing to unveil the multifaceted
benefits of these fascinating ingredients, which dovetails with their
well-established tolerability amongst consumers with sensitive skin unlike
many common skincare ingredients, including retinoids, Vitamin C and
exfoliating acids. On this basis, cannabinoids present a new class of active
ingredients that warrant a role in any skincare routine."
For further information please contact:
Cellular Goods
Anna Chokina via Tancredi +44 207 887 7633
Chief Executive
Investor Relations ir@cellular-goods.com
Tennyson Securities
Corporate Broker
Peter Krens +44 207 186 9030
Novum Securities
Corporate Broker
Colin Rowbury
Jon Belliss +44 207 399 9427
Tancredi Intelligent Communication
Media Relations
Helen Humphrey +44 744 922 6720
Gabriela Amaya Garcia +44 791 503 5294
Charlie Hobbs +44 789 755 7112
cellulargoods@tancredigroup.com (mailto:cellulargoods@tancredigroup.com)
About Cellular Goods PLC:
Cellular Goods is a UK-based wellness company that provides premium products
based on lab-made cannabinoids. It was established in August 2018 to develop
efficacy-led and research-backed cannabinoid-powered wellness products. The
initial focus is on three product verticals: Function Better, Feel Better and
Look Better. These three verticals encompass Cellular Goods' premium CBG
skincare and CBD ingestible and topical athletic recovery products, with the
first products launched in December 2021 initially through the Company's
website. The Company's shares are listed on the main market of the London
Stock Exchange. www.cellular-goods.com (http://www.cellular-goods.com)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUPUWGBUPPPWA